Vertex Pharmaceuticals Valuation

<div class='logoBackup' style='background:#754DEB;color: white;font-size:3em;;'>VRT</div>
VRTX -- USA Stock  

Earning Report: February 4, 2020  

Vertex Pharmaceuticals has current Real Value of $253.81 per share. The regular price of the company is $234.15. At this time the company appears to be undervalued. This module measures value of Vertex Pharmaceuticals from inspecting the company fundamentals such as Return On Equity of 22.09 , Operating Margin of 25.01  and Shares Outstanding of 257.15 M as well as reviewing its technical indicators and Probability Of Bankruptcy. In general, we recommend to buy undervalued stocks and to dispose of overvalued stocks since at some point securities prices and their ongoing real values will draw towards each other.
Undervalued
Today
234.15
January 18, 2020
210.74
Downside
253.81
Real Value
257.68
Upside
Vertex Pharmaceuticals is very steady asset. Calculation of real value of Vertex Pharmaceuticals is based on 3 months time horizon. Increasing Vertex Pharmaceuticals time horizon generally increases accuracy of value calculation and significantly improves predictive power of the methodology used.
Investments

Valuation Drivers Correlation

Click cells to compare fundamentals   View All Correlations
Vertex Pharmaceuticals Incorpor Valuation Data Drivers
Net Income Per Employee    Enterprise Value    Market Capitalization    

Vertex Pharmaceuticals Market Cap

Vertex Pharmaceuticals Incorpor is rated below average in market capitalization category among related companies. Market capitalization of Biotechnology industry is at this time estimated at about 230.64 Billion. Vertex Pharmaceuticals totals roughly 55.96 Billion in market capitalization claiming about 24% of stocks in Biotechnology industry.
Capitalization  Workforce  Total debt  Valuation  Revenue
Horizon     30 Days    Login   to change
Vertex Pharmaceuticals Incorpor is rated below average in price to book category among related companies. It is rated below average in price to sales category among related companies fabricating about  1.45  of Price to Sales per Price to Book.

Valuation Basics

Vertex Pharmaceuticals Enterprise Value Fundamentals

Quick Ratio3.20
Earnings Quarterly Growth-55.30%
Revenue Growth21.10%
Enterprise Value To Ebitda61.34
Earnings Growth-55.60%
Enterprise Value To Revenue15.34

Valuation Indicators

Vertex Pharmaceuticals Valuation Fundamental Ratios

Also please take a look at World Market Map. Please also try Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Company logos by clearbit